Clinical trial
Treating Schizophrenia by Correcting Abnormal Brain Development
NCT00179465 · Beth Israel Deaconess Medical Center, Other · Active, not recruiting
Key facts
| NCT number | NCT00179465 |
|---|---|
| Title | Treating Schizophrenia by Correcting Abnormal Brain Development |
| Official title | Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex |
| Lead sponsor | Beth Israel Deaconess Medical Center, Other |
| Collaborators | Dartmouth-Hitchcock Medical Center |
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Tiagabine, Placebo |
| Enrollment | 36 |
| Start date | Nov 1, 2003 |
| Primary completion | Sep 1, 2026 |
| Completion | Sep 1, 2026 |
| First posted | Sep 16, 2005 |
| Last update posted | Jan 27, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: